Investigation Announcement by Glancy Prongay & Murray LLP
Glancy Prongay & Murray LLP, a prominent law firm dedicated to shareholder rights, has revealed the initiation of an investigation into the actions of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). This investigation aims to assess whether the company has potentially violated federal securities laws, a development that could significantly affect investors.
Details of the Allegations Against Regeneron
Recent reports indicate that the US Department of Justice filed a complaint against Regeneron under the False Claims Act, which raises serious questions about the company's practices. The complaint suggests that Regeneron knowingly misrepresented Medicare reimbursement costs for their drug Eylea. By allegedly excluding certain discounts in their reports, the company may have artificially inflated drug costs, which could result in substantial financial repercussions for investors.
Impact of the Allegations on Stock Performance
Following the announcement of these allegations, Regeneron experienced a notable decline in its stock price. Within just two trading days, the stock plummeted by over $30, closing at $904.70 per share. This significant drop highlights the volatility and risks associated with Regeneron’s stock in light of these serious accusations.
Regeneron’s Financial Performance and Market Response
On October 31, 2024, Regeneron disclosed its third-quarter financial results, revealing mixed news for investors. The company reported a modest increase in U.S. net sales for Eylea, reaching $1.54 billion. However, this figure came alongside reports of lower selling prices compared to the previous year, indicating potential challenges ahead.
Market analysts responded to the report with caution, noting that Regeneron's earnings did not meet expectations, particularly regarding their higher dose Eylea variant. As a result, the company's stock took another hit, falling nearly 10% to close at $838.20 per share on the same day. This downturn serves as a reminder of the market's sensitivity to both corporate performance and regulatory scrutiny.
Steps for Affected Investors
For investors who have suffered financial losses due to their exposure to Regeneron, it is crucial to seek information about their rights and options. Glancy Prongay & Murray LLP encourages anyone impacted by these developments to reach out for assistance. Investors can submit their information on the firm’s website to learn more about potential claims and recovery options.
Whistleblower Program and Investigation Insights
The investigation could also provide opportunities for whistleblowers. Individuals with non-public information about Regeneron are encouraged to report their findings, as they may become eligible for rewards under the SEC Whistleblower Program. This program offers whistleblowers up to 30% of any successful recovery achieved by the SEC based on their information.
GPM urges individuals to take part in this process to support accountability and transparency in corporate practices.
About Glancy Prongay & Murray LLP
Established as a premier law firm, Glancy Prongay & Murray LLP focuses on representing investors and consumers engaged in complex securities and class action litigation. Consistently recognized for their achievements, GPM's legal experts have recovered billions of dollars through diligent representation against corporate wrongdoing across multiple sectors including healthcare, technology, energy, and many others.
With a commitment to excellence, GPM’s knowledgeable attorneys engage in various cases involving breaches of securities laws, providing investors with the legal counsel they need to navigate complex financial disputes.
Frequently Asked Questions
What is the nature of the investigation into Regeneron Pharmaceuticals?
The investigation concerns possible violations of federal securities laws related to the company’s Medicare reimbursement practices for their drug Eylea.
How has Regeneron's stock been affected by recent news?
Regeneron’s stock saw significant declines following the announcement of the DOJ complaint and disappointing earnings results, reflecting investor concerns about the company’s future.
What should investors do if they’ve suffered losses?
Investors experiencing losses are encouraged to reach out to Glancy Prongay & Murray LLP for potential claims and to understand their rights regarding future actions.
How does the SEC Whistleblower Program work?
The SEC Whistleblower Program incentivizes individuals with non-public information about securities violations to report their findings, offering financial rewards for valid claims.
What types of cases does Glancy Prongay & Murray LLP handle?
GPM specializes in securities litigation and class action lawsuits, addressing various corporate misconduct scenarios across industries.
